Schrödinger, Inc. (NASDAQ:SDGR – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $32.11.
SDGR has been the topic of several analyst reports. KeyCorp upped their price target on shares of Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. BMO Capital Markets boosted their price objective on shares of Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th.
Check Out Our Latest Research Report on SDGR
Institutional Inflows and Outflows
Schrödinger Price Performance
SDGR stock opened at $24.49 on Wednesday. The stock has a market capitalization of $1.78 billion, a P/E ratio of -10.47 and a beta of 1.61. Schrödinger has a fifty-two week low of $16.67 and a fifty-two week high of $33.63. The business has a 50-day moving average of $21.70 and a 200-day moving average of $20.30.
Schrödinger (NASDAQ:SDGR – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.12). The business had revenue of $35.30 million for the quarter, compared to the consensus estimate of $41.25 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The company’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.86) earnings per share. Equities analysts expect that Schrödinger will post -2.37 EPS for the current year.
Schrödinger Company Profile
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Further Reading
- Five stocks we like better than Schrödinger
- What is Forex and How Does it Work?
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Transportation Stocks Investing
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.